Galapagos NV

502 articles with Galapagos NV

• 

  Gilead Increases Stake in Galapagos with 10-Year Deal Worth More than $5 Billion

  7/15/2019

  Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos' pipeline.

• Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

  7/14/2019

  Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration.

• Galapagos increases share capital through warrant exercises on 20 June 2019

  6/20/2019

  Galapagos NV announces a share capital increase arising from warrant exercises.

• Galapagos NV received a transparency notification from The Capital Group Companies, Inc.

  6/17/2019

  Galapagos NV received a transparency notification from The Capital Group Companies, Inc.

• Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

  6/11/2019

  Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.

• Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)

  5/29/2019

  Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions

• Galapagos reports on historic first quarter 2019

  4/25/2019

  Galapagos NV presents financial results and highlights the key events for the first quarter of 2019.

• MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients

  4/23/2019

  MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

• Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

  4/23/2019

  Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

• Galapagos creates new warrant plans

  4/10/2019

  Galapagos NV announced that its board of directors created 2,070,000 warrants under new warrant plans for the benefit of the employees, directors, and a consultant of the company and its subsidiaries.

• Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2018

  3/29/2019

  Galapagos NV published its annual report for the financial year 2018.

• 

  Gilead and Galapagos Nab Phase III Wins in Two RA Trials

  3/29/2019

  Gilead Sciences and Belgium-based Galapagos NV reported positive late-stage results from its FINCH 1 and FINCH 3 rheumatoid arthritis studies.

• Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients

  3/28/2019

  Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone

• Galapagos increases share capital through warrant exercises on 20 March 2019

  3/20/2019

  Galapagos NV announces a share capital increase arising from warrant exercises.

• 

  Positive Readouts for Axsome and Galapagos Could Cause Stocks to Skyrocket, Analyst Predicts

  3/8/2019

  In February, Galapagos NV Chief Executive Officer Onno van de Stolpe promised that 2019 will be a “data rich year” for the Belgium-based company and its lead product, filgotinib.

• Firmly on our way to becoming a fully integrated biopharma company

  2/21/2019

  FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability

• Evotec and Galapagos enter into collaboration in the field of fibrosis

  2/7/2019

  Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG, and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications.

• Sands Capital reports 5.7% holding in Galapagos

  1/8/2019

  Galapagos NV received a transparency notification from Sands Capital Management, LLC.

• Galapagos starts first Phase 1 trial with Toledo compound

  1/7/2019

  Novel target class with dual action in inflammatory disorders

• Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

  1/6/2019

  Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with '1690 in IPF.